Title

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Document Type

Article

Publication Date

8-21-2018

Abstract

Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Share

COinS